Published in Am J Med on January 01, 1973
Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev (1999) 12.90
Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest (1982) 4.71
General primer-mediated PCR for detection of Aspergillus species. J Clin Microbiol (1994) 2.81
Damage to hyphal forms of fungi by human leukocytes in vitro. A possible host defense mechanism in aspergillosis and mucormycosis. Am J Pathol (1978) 2.66
Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother (1996) 2.52
Detection of Aspergillus fumigatus by polymerase chain reaction. J Clin Microbiol (1993) 2.51
In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother (1996) 1.97
Galactomannan antigenemia in invasive aspergillosis. Infect Immun (1979) 1.94
Immunodiagnosis of aspergillosis. Clin Microbiol Rev (1991) 1.90
Detection of Aspergillus antigens associated with invasive infection. J Clin Microbiol (1990) 1.83
Molecular typing of environmental and patient isolates of Aspergillus fumigatus from various hospital settings. J Clin Microbiol (1998) 1.68
Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax (1991) 1.66
Significance of Aspergillus species isolated from respiratory secretions in the diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol (1980) 1.64
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis (2016) 1.58
Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother (1995) 1.48
Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother (1989) 1.48
Detection of galactomannan antigenemia by enzyme immunoassay in experimental invasive aspergillosis. J Clin Microbiol (1987) 1.44
Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrob Agents Chemother (1998) 1.43
Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature. Infection (2006) 1.40
Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1996) 1.35
Identification and characterization of an immunodominant 58-kilodalton antigen of Aspergillus fumigatus recognized by sera of patients with invasive aspergillosis. Infect Immun (1991) 1.30
Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother (1994) 1.20
Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob Agents Chemother (1990) 1.19
Use of immunoblotting to detect Aspergillus fumigatus antigen in sera and urines of rats with experimental invasive aspergillosis. J Clin Microbiol (1990) 1.15
Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica (Cairo) (2013) 1.14
Apparent pulmonary mycetoma following invasive aspergillosis in neutropenic patients. Thorax (1988) 1.09
Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression. Arch Surg (1997) 1.05
Necrotising pulmonary aspergillosis complicating the management of patients with obstructive airways disease. Thorax (1983) 1.05
Pulmonary carcinosarcoma initially presenting as invasive aspergillosis: a case report of previously unreported combination. Diagn Pathol (2010) 1.02
Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient. Thorax (1993) 1.00
Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother (2000) 0.99
Diagnosis of invasive aspergillus tracheobronchitis facilitated by endobronchial ultrasound-guided transbronchial needle aspiration: a case report. J Med Case Rep (2009) 0.97
Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother (1997) 0.95
Aspergillus thyroiditis: a review of the literature to highlight clinical challenges. Eur J Clin Microbiol Infect Dis (2012) 0.89
Model of recurrent pulmonary aspergillosis in rats. J Clin Microbiol (1991) 0.87
Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation. Clin Microbiol Rev (1997) 0.85
Murine model of invasive pulmonary aspergillosis following an earlier stage, noninvasive Aspergillus infection. J Clin Microbiol (1996) 0.83
Aspergillus granuloma of the trigeminal ganglion. J Neurol Neurosurg Psychiatry (1981) 0.82
Pulmonary embolism in patients with acute leukemia and severe thrombocytopenia. West J Med (1981) 0.82
Aspergillus terreus causing invasive pulmonary aspergillosis with air-crescent sign. J Natl Med Assoc (1986) 0.79
Aspergillus thyroiditis: a complication of respiratory tract infection in an immunocompromised patient. Case Rep Endocrinol (2013) 0.79
Pseudomembranous necrotising bronchial aspergillosis complicating chronic airways limitation. Thorax (1995) 0.79
How to treat fungal infections in ICU patients. BMC Infect Dis (2015) 0.78
History of medical mycology in the united states. Clin Microbiol Rev (1996) 0.78
Heterogeneity among Isolates Reveals that Fitness in Low Oxygen Correlates with Aspergillus fumigatus Virulence. MBio (2016) 0.77
Superadded aspergillosis on carcinoid bronchial adenoma leading to delayed diagnosis. Postgrad Med J (1990) 0.76
Disseminated aspergillosis in a patient with ocular reticulum cell sarcoma. Br J Ophthalmol (1987) 0.75
Acute lymphocytic leukemia with superimposed invasive aspergillosis and pneumopericardium successfully treated with voriconazole. Proc (Bayl Univ Med Cent) (2014) 0.75
Aspergillus in a cervico-vaginal smear of an adult postmenopausal female: An unusual case. J Cytol (2009) 0.75
Respiratory fungus allergy and infection. Proc R Soc Med (1975) 0.75
Breast cancer, cough and vesicular eruptions. Can Med Assoc J (1980) 0.75
Disseminated aspergillosis following radiation therapy for medulloblastoma. Postgrad Med J (1985) 0.75
Primary epitopes of chicken egg yolk antibodies to peptidophosphogalactomannan. Clin Diagn Lab Immunol (1998) 0.75
Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med (1991) 7.83
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet (2001) 7.31
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 7.14
Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1986) 6.79
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Effect of a general practitioner's consulting style on patients' satisfaction: a controlled study. BMJ (1990) 6.15
The lux autoinducer regulates the production of exoenzyme virulence determinants in Erwinia carotovora and Pseudomonas aeruginosa. EMBO J (1993) 5.35
Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J Clin Microbiol (1985) 5.22
Referral to hospital: perceptions of patients, general practitioners and consultants about necessity and suitability of referral. Fam Pract (1987) 5.11
Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron (1998) 4.92
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex. Rev Infect Dis (1987) 4.54
Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol (1988) 4.47
Comparison of criteria derived by government and patients for evaluating general practitioner services. BMJ (1989) 4.36
Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med (1981) 4.31
Legionnaires' disease: clinical features of 24 cases. Ann Intern Med (1978) 4.30
Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann Intern Med (1978) 4.15
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Treatment of infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1985) 4.02
Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis (1985) 4.00
Laboratory diagnosis of Legionnaires' disease. Am Rev Respir Dis (1980) 3.95
Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents. Antimicrob Agents Chemother (1977) 3.91
Diagnostic criteria for Walker-Warburg syndrome. Am J Med Genet (1989) 3.74
Adaptive wavelet thresholding for image denoising and compression. IEEE Trans Image Process (2000) 3.67
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med (1992) 3.65
Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ (1999) 3.62
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ (2000) 3.45
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 3.41
Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet (1997) 3.32
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis (1972) 3.28
Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med (1994) 3.25
Continuous high-grade mycobacterium avium-intracellulare bacteremia in patients with the acquired immune deficiency syndrome. Am J Med (1985) 3.19
Reasons for referral to hospital: extent of agreement between the perceptions of patients, general practitioners and consultants. Fam Pract (1986) 3.14
Comparative recovery of bacteria and yeasts from lysis-centrifugation and a conventional blood culture system. J Clin Microbiol (1983) 3.09
Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother (1987) 3.06
Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (1997) 3.06
A reevaluation of cancer incidence near the Three Mile Island nuclear plant: the collision of evidence and assumptions. Environ Health Perspect (1997) 3.04
Investigation of burnout in a sample of British general practitioners. Br J Gen Pract (1995) 3.03
Hemagglutination typing of Escherichia coli: definition of seven hemagglutination types. J Clin Microbiol (1980) 3.03
Intraorbital wood. Detection by magnetic resonance imaging. Ophthalmology (1990) 2.99
Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med (1977) 2.92
Measuring general practitioner referrals: patient, workload and list size effects. J R Coll Gen Pract (1988) 2.91
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry (1995) 2.90
Isolation of Legionella pneumophila from hospital shower heads. Ann Intern Med (1981) 2.89
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother (1973) 2.85
The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther (2003) 2.83
Hemolysin and K antigens in relation to serotype and hemagglutination type of Escherichia coli isolated from extraintestinal infections. J Clin Microbiol (1981) 2.82
In vitro studies of piperacilin, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.82
Legionnaires' disease: report of sixty-five nosocomially acquired cases of review of the literature. Medicine (Baltimore) (1980) 2.81
Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann Intern Med (1984) 2.80
Immunologic diagnosis of Legionnaires' disease: cross-reactions with anaerobic and microaerophilic organisms and infections caused by them. J Infect Dis (1980) 2.76
Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol (1999) 2.73
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
Species identification of coagulase-negative staphylococcal isolates from blood cultures. J Clin Microbiol (1982) 2.71
Preferences of healthy and ill patients for style of general practitioner care: implications for workload and financial incentives under the new contract. Br J Gen Pract (1991) 2.66
Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62
Telephone consultations in general practice: an additional or alternative service? Br J Gen Pract (1995) 2.62
Epstein-Barr virus persistence and virus-associated tumours. Lancet (1994) 2.60
Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa. Appl Microbiol (1971) 2.60
A comparison of knee joint motion patterns between men and women in selected athletic tasks. Clin Biomech (Bristol, Avon) (2001) 2.56
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis (1986) 2.56
Nontuberculous mycobacterial infections: a clinical review. Infection (2004) 2.56
Septicemia due to Aeromonas hydrophila: clinical and immunologic aspects. J Infect Dis (1973) 2.55
Oxidative damage to DNA in diabetes mellitus. Lancet (1996) 2.54
Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis (1990) 2.51
Patients' responses to risk information about the benefits of treating hypertension. Br J Gen Pract (2001) 2.50
Patients' views of priority setting in health care: an interview survey in one practice. BMJ (1995) 2.50
Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest (1979) 2.50
Susceptibility of Legionella pneumophila to twenty antimicrobial agents. Antimicrob Agents Chemother (1980) 2.49
Voltage-activated calcium channels that must be phosphorylated to respond to membrane depolarization. Proc Natl Acad Sci U S A (1987) 2.48
Legionnaires' disease: unusual clinical and laboratory features. Ann Intern Med (1980) 2.46
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med (1990) 2.45
Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia. J Lab Clin Med (1975) 2.41
Opportunistic infection in previously healthy women. Initial manifestations of a community-acquired cellular immunodeficiency. Ann Intern Med (1982) 2.41
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer (1974) 2.36
Legionella infections: a review of five years of research. Rev Infect Dis (1983) 2.30
Radioimmunoassay, acetylating radio-enzymatic assay, and microbioassay of gentamicin: a comparative study. J Lab Clin Med (1975) 2.30
Pneumothorax in AIDS. Ann Intern Med (1991) 2.29
Candidiasis: detection by gas-liquid chromatography of D-arabinitol, a fungal metabolite, in human serum. Science (1979) 2.26
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
Nocardia asteroides infection complicating neoplastic disease. Am J Med (1971) 2.23
Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli. Antimicrob Agents Chemother (1980) 2.23
Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene (1998) 2.22
Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med (1993) 2.22
Isolation of a new serotype of legionnaires' disease bacterium. Lancet (1978) 2.21
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
A short 5' flanking region containing conserved sequences is required for silkworm alanine tRNA gene activity. Proc Natl Acad Sci U S A (1983) 2.19
The prevalence of yeasts in clinical specimens from cancer patients. Am J Clin Pathol (1980) 2.19
Functional conservation of atonal and Math1 in the CNS and PNS. Development (2000) 2.18